Compounds > sauchinone
Page last updated: 2024-11-12

sauchinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sauchinone: isolated from Saururus chinensis; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
Saururusgenus[no description available]SaururaceaeA plant family of the order Piperales, subclass Magnoliidae class Magnoliopsida. Members contain sauristolactam, and aristololactam BII.[MeSH]

Cross-References

ID SourceID
PubMed CID11725801
CHEMBL ID520054
SCHEMBL ID1498622
MeSH IDM0366360

Synonyms (16)

Synonym
sauchinone
CHEMBL520054
S9406
177931-17-8
SCHEMBL1498622
J-011331
(5ar,5a1r,7r,8s,8ar,14as)-7,8-dimethyl-5a,5a1,6,7,8,8a-hexahydro-5h-benzo[kl]bis([1,3]dioxolo)[4,5-b:4',5'-g]xanthen-5-one
AKOS030631736
HY-N0613
(1s,12r,13s,14r,16r,23r)-13,14-dimethyl-2,6,8,20,22-pentaoxahexacyclo[10.10.1.01,19.03,11.05,9.016,23]tricosa-3,5(9),10,18-tetraen-17-one
mfcd08702698
CCG-268111
CS-0009611
AC-34741
DTXSID701318550
AS-77171

Research Excerpts

Overview

Sauchinone is a phytochemical known as a nitric oxide (NO) inhibitor. It has been used as a traditional Oriental medicine to treat fever, jaundice, and various inflammatory diseases.

ExcerptReferenceRelevance
"Sauchinone is a phytochemical known as a nitric oxide (NO) inhibitor. "( Sauchinone blocks methamphetamine-induced hyperlocomotion and place preference in mice.
Hwang, M; Kim, DH; Yang, CH, 2013)		3.28
"ent-Sauchinone is a polyphenolic compound found in plants belonging to the lignan family. "( Inhibitory effect of ent-Sauchinone on amyloidogenesis via inhibition of STAT3-mediated NF-κB activation in cultured astrocytes and microglial BV-2 cells.
Choi, DY; Ham, YW; Han, SB; Hong, JT; Hwang, BY; Hwang, CJ; Hyun, BK; Jung, YY; Kim, JH; Lee, HP; Lee, SM; Seo, HO; Sok, CH; Song, SY, 2014)		1.26
"Sauchinone is a pharmacologically active compound isolated from Saururus chinensis, which has been used as a traditional Oriental medicine to treat fever, jaundice, and various inflammatory diseases. "( Sauchinone exerts anticancer effects by targeting AMPK signaling in hepatocellular carcinoma cells.
Jang, EJ; Kim, CH; Kim, YW; Lee, JH, 2017)		3.34
"Sauchinone is a lignan isolated from Saururus chinensis known to suppress nitric oxide (NO) activity. "( Protective effect of sauchinone on methamphetamine-induced neurotoxicity in mice.
Hwang, M; Jang, EY; Lee, JR; Park, KA; Yang, CH, 2012)		2.14

Effects

Sauchinone has been shown to modulate the expression of inflammatory factors through the nuclear factor-kappa B (NF-κB) signaling pathway. Sauchinone exerts potent hepatoprotective, anti-inflammatory and inhibitory effects on bone resorption.

ExcerptReferenceRelevance
"ent-Sauchinone has been shown to modulate the expression of inflammatory factors through the nuclear factor-kappa B (NF-κB) signaling pathway."( Inhibitory effect of ent-Sauchinone on amyloidogenesis via inhibition of STAT3-mediated NF-κB activation in cultured astrocytes and microglial BV-2 cells.
Choi, DY; Ham, YW; Han, SB; Hong, JT; Hwang, BY; Hwang, CJ; Hyun, BK; Jung, YY; Kim, JH; Lee, HP; Lee, SM; Seo, HO; Sok, CH; Song, SY, 2014)		1.19
"Sauchinone has been shown to exert potent hepatoprotective, anti-inflammatory and inhibitory effects on bone resorption. "( Sauchinone protects pancreatic β cells against cytokine-mediated toxicity.
Jeong, GS; Kim, YC; Kwon, KB; Lee, DS; Park, BH, 2011)		3.25
"Sauchinone has been known to have anti-inflammatory and antioxidant effects. "( Protective effect of sauchinone against regional myocardial ischemia/reperfusion injury: inhibition of p38 MAPK and JNK death signaling pathways.
Bae, HB; Jeong, CW; Kim, SJ; Kwak, SH; Lee, HJ; Lee, J; Seo, CS; Son, JK; Yoo, KY, 2012)		2.14
"Sauchinone has been shown to modulate the expression of inflammatory factors through nuclear factor-kappa B (NF-κB) signaling pathway."( Sauchinone suppresses lipopolysaccharide-induced inflammatory responses through Akt signaling in BV2 cells.
Choi, YH; Han, MH; Hwang, M; Jang, EY; Yang, CH, 2012)		2.54

Actions

ExcerptReferenceRelevance
"Sauchinone did not inhibit both NMDA-induced cell membrane depolarization and intracellular calcium influx."( Sauchinone reduces oxygen-glucose deprivation-evoked neuronal cell death via suppression of intracellular radical production.
Choi, IY; Kim, WK; Park, YK; Yan, H, 2009)		2.52

Treatment

Sauchinone treatment suppressed the reactive oxygen species (ROS) production and NADPH oxidase (NOX) activity in Ang II-induced VSMCs. Treatment with sauchinone decreased the level of phosphorylated ribosomal protein S6 (rpS6) in LPS-stimulated neutrophils.

ExcerptReferenceRelevance
"Sauchinone treatment also enhanced the cytotoxicity of SW840 and HCT116 cells co-cultured with CD8"( Sauchinone Inhibits the Proliferation and Immune Invasion Capacity of Colorectal Cancer Cells through the Suppression of PD-L1 and MMP2/MM9.
Gao, J; Ji, Z; Liang, Y; Lu, Y; Wang, J; Ye, J; Yu, M, 2023)		3.07
"Sauchinone treatment suppressed the reactive oxygen species (ROS) production and NADPH oxidase (NOX) activity in Ang II-induced VSMCs."( Sauchinone inhibits angiotensin II-induced proliferation and migration of vascular smooth muscle cells.
Geng, X; He, X; Huang, X; Li, X; Ma, S; Wang, Y; Xing, Y, 2020)		2.72
"Sauchinone treatment attenuated EIF4EBP1 expression and cell cycle-related protein levels."( Sauchinone: a prospective therapeutic agent-mediated EIF4EBP1 down-regulation suppresses proliferation, invasion and migration of lung adenocarcinoma cells.
Ai, XP; Feng, J; He, M; Li, SQ; Liu, F; Yang, M, 2020)		2.72
"Sauchinone treatment activated LKB1, which led to AMPK activation: these events contributed to cell survival."( Efficacy of sauchinone as a novel AMPK-activating lignan for preventing iron-induced oxidative stress and liver injury.
Brooks, JS; Hwang, SJ; Kang, HE; Kim, SC; Kim, SG; Kim, YW; Lee, MG; Lee, SM; Shin, SM, 2009)		1.45
"Sauchinone treatment induced modifier subunit of glutamate-cysteine ligase, NAD(P)H:quinone oxidoreductase-1 (NQO1) and heat shock protein 32 in the liver, which was abolished by Nrf2 deficiency."( Nrf2-mediated liver protection by sauchinone, an antioxidant lignan, from acetaminophen toxicity through the PKCδ-GSK3β pathway.
Hwang, SJ; Kay, HY; Kim, SG; Kim, YW; Ryu, DH; Sung, SH, 2011)		1.37
"Sauchinone treatment also inhibited the methamphetamine-induced activation of glia cells and the production of NO via a blockade of inducible NO synthase protein expression."( Protective effect of sauchinone on methamphetamine-induced neurotoxicity in mice.
Hwang, M; Jang, EY; Lee, JR; Park, KA; Yang, CH, 2012)		1.42
"Treatment with sauchinone decreased the level of phosphorylated ribosomal protein S6 (rpS6) in LPS-stimulated neutrophils."( Sauchinone, a lignan from Saururus chinensis, attenuates neutrophil pro-inflammatory activity and acute lung injury.
Bae, HB; Han, HJ; Kwak, SH; Li, M; Seo, CS; Son, JK; Song, SW, 2013)		2.17
"Pre-treatment with sauchinone increased the viability of cytokine-treated RINm5F cells at concentrations of 20-40 μM."( Sauchinone protects pancreatic β cells against cytokine-mediated toxicity.
Jeong, GS; Kim, YC; Kwon, KB; Lee, DS; Park, BH, 2011)		2.13

Pharmacokinetics

ExcerptReferenceRelevance
" These pharmacokinetic data of sauchinone provide an important basis for preclinical applications and experimental methods can be adjusted to evaluate the pharmacokinetics of natural products in mice."( Pharmacokinetics, tissue distribution, and tentative metabolite identification of sauchinone in mice by microsampling and HPLC-MS/MS methods.
Chin, YW; Choi, YH; Han, SY; Kim, YJ; Seo, JS, 2015)		0.93
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1064261Antiplatelet activity against New Zealand white rabbit platelets assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated at 100 uM for 2 mins before challenge measured after 2 mins by spectrophotometry2014Journal of natural products, Jan-24, Volume: 77, Issue:1
Lignans from the aerial parts of Saururus chinensis: isolation, structural characterization, and their effects on platelet aggregation.
AID376573Hepatoprotective activity in Wistar rat CCL4-damaged hepatocyte assessed as blockade of glutamic pyruvic transaminase release at 100 uM relative to control2000Journal of natural products, Jul, Volume: 63, Issue:7
Hepatoprotective diastereomeric lignans from Saururus chinensis herbs.
AID1064259Antiplatelet activity against New Zealand white rabbit platelets assessed as inhibition of PAF-induced platelet aggregation preincubated at 100 uM for 2 mins before challenge measured after 2 mins by spectrophotometry2014Journal of natural products, Jan-24, Volume: 77, Issue:1
Lignans from the aerial parts of Saururus chinensis: isolation, structural characterization, and their effects on platelet aggregation.
AID1064264Antiplatelet activity against New Zealand white rabbit platelets assessed as inhibition of ADP-induced platelet aggregation preincubated at 100 uM for 2 mins before challenge measured after 2 mins by spectrophotometry2014Journal of natural products, Jan-24, Volume: 77, Issue:1
Lignans from the aerial parts of Saururus chinensis: isolation, structural characterization, and their effects on platelet aggregation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (50)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (20.00)29.6817
2010's30 (60.00)24.3611
2020's10 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.06 (24.57)
Research Supply Index3.93 (2.92)
Research Growth Index5.35 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other50 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
acetone
methyl ketone : A ketone of formula RC(=O)CH3 (R =/= H).		2.0810ketone body;
methyl ketone;
propanones;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
human metabolite;
polar aprotic solvent
nitrites
Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)		2.1310monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species		human metabolite
acetaminophen
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.		7.0610acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
aspirin
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.		2.110benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
chlorzoxazone
Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202). chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.		2.17101,3-benzoxazoles;
heteroaryl hydroxy compound;
organochlorine compound		muscle relaxant;
sedative
molsidomine
Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.. molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.		2.0810ethyl ester;
morpholines;
oxadiazole;
zwitterion		antioxidant;
apoptosis inhibitor;
cardioprotective agent;
nitric oxide donor;
vasodilator agent
pd 98059
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.		2.0610aromatic amine;
monomethoxyflavone		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
sibutramine
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride		2.1710organochlorine compound;
tertiary amino compound		anti-obesity agent;
serotonin uptake inhibitor
ticlopidine
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.. ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.		2.1710monochlorobenzenes;
thienopyridine		anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
carbon tetrachloride
Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.		2.4420chlorocarbon;
chloromethanes		hepatotoxic agent;
refrigerant
tert-butylhydroperoxide
tert-Butylhydroperoxide: A direct-acting oxidative stress-inducing agent used to examine the effects of oxidant stress on Ca(2+)-dependent signal transduction in vascular endothelial cells. It is also used as a catalyst in polymerization reactions and to introduce peroxy groups into organic molecules.. tert-butyl hydroperoxide : An alkyl hydroperoxide in which the alkyl group is tert-butyl. It is widely used in a variety of oxidation processes.		2.0510alkyl hydroperoxideantibacterial agent;
oxidising agent
phenylhydrazine
[no description available]		2.0510phenylhydrazinesxenobiotic
methamphetamine
Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.		2.4820amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
malondialdehyde
Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.		210dialdehydebiomarker
trinitrobenzenesulfonic acid
Trinitrobenzenesulfonic Acid: A reagent that is used to neutralize peptide terminal amino groups.. 2,4,6-trinitrobenzenesulfonic acid : The arenesulfonic acid that is benzenesulfonic acid with three nitro substituents in the 2-, 4- and 6-positions.		2.6620arenesulfonic acid;
C-nitro compound		epitope;
explosive;
reagent
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		2.1710azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
clopidogrel
Clopidogrel: A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION.. clopidogrel : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a methoxycarbonyl group (the S enantiomer). A P2Y12 receptor antagonist, it is used to inhibit blood clots and prevent heart attacks.		2.5320methyl ester;
monochlorobenzenes;
thienopyridine		anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
cv 3988
CV 3988: platelet activating factor antagonist; structure given in first source		2.110
fraxinellone
fraxinellone: structure given in first source; RN given for (3R-cis)-isomer		7.05102-benzofurans
angiotensin ii
Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).		7.2510amino acid zwitterion;
angiotensin II		human metabolite
sb 203580
[no description available]		2.0510imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
benzofurans
Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.		2.0510
lignans
Lignans: A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)		3.84110
arachidonic acid
icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.		2.0510icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite
silybin
[no description available]		210
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		2.5220prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
quercitrin
[no description available]		2.110alpha-L-rhamnoside;
monosaccharide derivative;
quercetin O-glycoside;
tetrahydroxyflavone		antileishmanial agent;
antioxidant;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.14.18.1 (tyrosinase) inhibitor;
plant metabolite
Licarin A
[no description available]		2.110benzofurans
4-hydroxy-2-nonenal
4-hydroxy-2-nonenal: cytotoxic product from peroxidation of liver microsomal lipids; RN given refers to cpd without isomeric designation. 4-hydroxynon-2-enal : An enal consisting of non-2-ene having an oxo group at the 1-position and a hydroxy group at the 4-position.. 4-hydroxynonenal : A monounsaturated fatty aldehyde that is nonanal that has undergone dehydrogenation to introduce a double bond at any position in the aliphatic chain and in which a hydrogen at position 4 has been replaced by a hydroxy group.		2.1104-hydroxynon-2-enal;
4-hydroxynonenal
staurosporine
staurosporinium : Conjugate acid of staurosporine.		7.0110ammonium ion derivative
transforming growth factor beta
Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.		2.1710
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		02.8220
Invasiveness, Neoplasm
[description not available]		03.3350
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.8220
Colorectal Cancer
[description not available]		07.610
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.610
Pulmonary Arterial Remodeling
[description not available]		02.2510
Innate Inflammatory Response
[description not available]		03.5270
Bowel Diseases, Inflammatory
[description not available]		02.6620
Colitis
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.		07.9430
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		03.5270
Inflammatory Bowel Diseases
Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.		02.6620
Diathesis
[description not available]		02.2510
Lung Adenocarcinoma
[description not available]		07.2510
Cancer of Lung
[description not available]		02.2510
Adenocarcinoma of Lung
A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.		02.2510
Lung Neoplasms
Tumors or cancer of the LUNG.		02.2510
Disease Exacerbation
[description not available]		02.2510
Cancer of Pancreas
[description not available]		02.2510
Carcinoma, Ductal, Pancreatic
[description not available]		02.2510
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		02.2510
Carcinoma, Pancreatic Ductal
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.		02.2510
Anoxemia
[description not available]		02.4110
Bone Cancer
[description not available]		02.4110
Osteogenic Sarcoma
[description not available]		02.4110
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		07.4110
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		02.4110
Osteosarcoma
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)		07.4110
Arthritis, Degenerative
[description not available]		02.5820
Osteoarthritis
A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.		07.5820
Cancer of Liver
[description not available]		02.5720
Liver Neoplasms
Tumors or cancer of the LIVER.		02.5720
Metastase
[description not available]		02.1710
Cancer of Stomach
[description not available]		02.1710
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		02.1710
Stomach Neoplasms
Tumors or cancer of the STOMACH.		02.1710
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.5820
Liver Steatosis
[description not available]		02.1710
Fatty Liver
Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.		02.1710
Skin Aging
The process of aging due to changes in the structure and elasticity of the skin over time. It may be a part of physiological aging or it may be due to the effects of ultraviolet radiation, usually through exposure to sunlight.		02.0810
Lung Injury, Acute
[description not available]		02.0810
Acute Lung Injury
A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).		07.0810
Vascular Diseases
Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.		02.110
E coli Infections
[description not available]		02.110
Escherichia coli Infections
Infections with bacteria of the species ESCHERICHIA COLI.		02.110
Cirrhosis, Liver
[description not available]		02.110
Liver Cirrhosis
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.		02.110
Hepatocellular Carcinoma
[description not available]		07.1510
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.1510
Asthma, Bronchial
[description not available]		02.0510
Rhinitis, Allergic, Nonseasonal
[description not available]		02.0510
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).		02.0510
Rhinitis, Allergic, Perennial
Inflammation of the mucous membrane of the nose similar to that found in hay fever except that symptoms persist throughout the year. The causes are usually air-borne allergens, particularly dusts, feathers, molds, animal fur, etc.		02.0510
Anoxia-Ischemia, Brain
[description not available]		02.0510
Hypoxia-Ischemia, Brain
A disorder characterized by a reduction of oxygen in the blood combined with reduced blood flow (ISCHEMIA) to the brain from a localized obstruction of a cerebral artery or from systemic hypoperfusion. Prolonged hypoxia-ischemia is associated with ISCHEMIC ATTACK, TRANSIENT; BRAIN INFARCTION; BRAIN EDEMA; COMA; and other conditions.		02.0510
Atrophy, Muscle
[description not available]		02.0610
Muscular Atrophy
Derangement in size and number of muscle fibers occurring with aging, reduction in blood supply, or following immobilization, prolonged weightlessness, malnutrition, and particularly in denervation.		02.0610
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.0710
Encephalopathy, Toxic
[description not available]		02.0710
Injury, Myocardial Reperfusion
[description not available]		02.0710
Degenerative Diseases, Central Nervous System
[description not available]		02.0710
Neurodegenerative Diseases
Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.		02.0710
Bone Loss, Osteoclastic
[description not available]		02.0310